Shares of Amgen Inc. (NASDAQ:AMGN) have earned an average recommendation of “Buy” from the twenty-six research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation, twelve have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $184.40.

Several equities research analysts have commented on AMGN shares. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $189.00 target price on shares of Amgen in a research note on Friday, June 30th. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Jefferies Group LLC restated a “hold” rating and set a $180.00 target price on shares of Amgen in a report on Monday, May 22nd. Credit Suisse Group set a $177.00 target price on shares of Amgen and gave the stock a “hold” rating in a report on Friday, July 14th. Finally, Morgan Stanley increased their target price on shares of Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, June 13th.

Amgen (NASDAQ AMGN) traded down 0.04% on Friday, hitting $180.64. 1,993,947 shares of the company were exchanged. The firm has a market cap of $131.81 billion, a price-to-earnings ratio of 16.45 and a beta of 1.35. The stock has a 50 day moving average price of $173.77 and a 200 day moving average price of $168.79. Amgen has a one year low of $133.64 and a one year high of $184.21.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. Amgen’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.84 earnings per share. On average, equities research analysts forecast that Amgen will post $12.57 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a dividend yield of 2.55%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio is presently 41.93%.

WARNING: “Amgen Inc. (AMGN) Given Average Recommendation of “Buy” by Analysts” was originally published by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/09/09/amgen-inc-amgn-given-average-recommendation-of-buy-by-analysts.html.

Institutional investors and hedge funds have recently made changes to their positions in the company. TrimTabs Asset Management LLC increased its position in shares of Amgen by 88.9% during the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after buying an additional 288 shares during the period. Alpha Omega Wealth Management LLC increased its position in shares of Amgen by 19.0% during the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. increased its position in shares of Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the period. Phocas Financial Corp. bought a new stake in shares of Amgen during the second quarter valued at about $110,000. Finally, American Beacon Advisors Inc. bought a new stake in shares of Amgen during the first quarter valued at about $106,000. Hedge funds and other institutional investors own 78.13% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.